The Official Comment of AHRMM to the United States Department of Health and Human Services Food and Drug Administration (FDA) regarding Unique Device Identification for Medical Devices Docket No. FDA-2011-N-0090

By AHRMM

AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA).

Related Resources

Webcast
GPO or Local/Self Contracting Series: Introduction and the GPO Role – Part 1
Allen Archer, System Director of Supply Chain at Houston Healthcare, leads a thought-leader panel discussion about the role of GPOs within the chan
On-Demand Educational Webinars
Leading Change: Aligning Clinicians and Physicians Using Evidenced Based Data
Learn how to drive organizational and cultural improvements by utilizing cost, quality, and outcome data in the decision making process. This webinar…
On-Demand Educational Webinars
Organizing and Executing Supply Chain Costs through Clinical Variation and Reduction
Reducing variability in products, supplies, pharmaceuticals, and other cost drivers is key to achieving margins in Medicare payment. This webinar…
Podcasts
The Meaningful Use 3 Rule
A short introduction to the CMS Meaningful Use 3 Rule and how implementing UDI within the healthcare setting and moving toward the full GS1 will re
On-Demand Educational Webinars
Day in the Life of CQO: Examples from the Field
A panel of health care industry leaders shares their insights and experiences in creating a best-practice supply chain that supports the intersection…
Webcast
GPO or Local/Self Contracting Series: Contracting Option Choices – Part 2
In part 2 of the GPO or Local/Self Contracting webcast series, the panel considers the multiple product categories and the process of choosing the